HC Wainwright Rates Structure Therapeutics (GPCR) buy

HC Wainwright reaffirmed a buy rating for Structure Therapeutics, setting a price target of $70 based on ongoing clinical developments, a 61.89% upside from the current price.

By EarningsIQ Research Desk · Published Jun 12, 2026, 9:14 PM EDT · Updated Jun 13, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Structure Therapeutics Inc. ($GPCR) "buy" with a $70 price target on June 11, 2026.

Since the rating, $GPCR is up 2.8% after 1 week, up 19.3% after 1 month and down 51.3% to date (from the $43.30 close on Jun 11, 2026).

GPCR Structure Therapeutics Inc.

$21.08 -69.05% year to date

Daily close · Oct 16, 2026

Key Points

On June 11, 2026, HC Wainwright reiterated its buy rating for Structure Therapeutics Inc. (GPCR) with a price target of $70, indicating upside from the stock's current price of $43.24.
Structure Therapeutics has a market cap of about $2.62 billion and is focusing on innovative treatments for obesity and other chronic diseases.
Analysts maintain a strong buy consensus on the stock, with an average price target of $105.78 from 15 analysts covering the company.

Get $GPCR trade alerts by text

We text you when insiders, Congress or big funds trade $GPCR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Structure Therapeutics Inc. alert may contain errors. Disclosures

HC Wainwright Maintains Buy Rating on GPCR

On June 11, 2026, HC Wainwright reaffirmed its buy rating for Structure Therapeutics Inc. (GPCR) on the NasdaqGM, setting a price target of $70. The stock was trading at $43.24, indicating a potential upside of about 62% from the current price. This price target reflects the firm's confidence in the company's ongoing clinical programs.

Why the Reiteration Matters

HC Wainwright's action comes as the company continues to develop its lead drug candidate, GSBR-1290, which is currently undergoing two phase 2 clinical trials aimed at treating obesity and related conditions. The market is keenly watching these developments, as successful trials could significantly impact the company's valuation and market presence. The firm's reiteration does not include a prior target, which emphasizes its strong belief in the stock's upside potential.

Institutional Support for Structure Therapeutics

While no peers were reported in this filing, Structure Therapeutics continues to attract interest from institutional investors. Recently, Xichen Lin, the Chief Scientific Officer, purchased 23,634 shares at an average price of $0.34 per share on June 25, 2026. This insider buying might suggest confidence in the company’s future prospects.

Stock Performance and Current Position

The stock is currently sitting at $43.24. This price is well above its 52-week low of $23.61 but significantly below its 52-week high of $94.90. With a forward P/E ratio being negative due to recent losses, investors are closely following the upcoming trials for clearer signals on profitability and growth potential. The recent target from HC Wainwright represents a substantial gap that investors might consider when evaluating their positions.

12-month forecast

$GPCR price target

Structure Therapeutics Inc. daily closes and this analyst's $70 target. Not advice.

Upcoming Earnings

Structure Therapeutics is set to report its next earnings on November 5, 2026. Investors will likely scrutinize the results and outlook closely, particularly in the context of ongoing trials and market conditions, as these factors will help shape the company's future performance.

What GPCR Does

Structure Therapeutics Inc. focuses on developing oral small molecule therapeutics aimed at treating chronic diseases. Its innovative approach in the biotechnology sector is particularly relevant as it works to address significant unmet medical needs, especially in obesity treatment.

What’s Next for GPCR

The reiterated buy rating from HC Wainwright underscores the potential for growth as the company advances its clinical programs. Investors will be watching closely for updates from the upcoming earnings report and any news regarding the outcomes of ongoing trials, which could provide further insight into the company’s direction and market response.